Common Pathophysiological Mechanisms Connecting Dyslipidemia and Hyperuricemia: a Narrative Review.

This review presents the pathophysiological changes underlying dyslipidemia and hyperuricemia. The way in which these health conditions influence each other is through insulin resistance, persistent inflammatory state, oxidative stress and endothelial damage. Insulin resistance influences lipid metabolism and uric acid elimination, leading to triglyceride accumulation and increased uric acid levels. Inflammatory mediators in adipose tissue and cytokine cascades maintain an inflammatory status, favor lipid peroxidation and decrease renal uric acid clearance. Reactive oxygen species amplified by oxidized lipoproteins and urate compromise nitric oxide signaling pathways and vascular homeostasis. Genetic and epigenetic alterations in genes involved in metabolic transport, cytokine regulation and microRNA expression also occur. This dual pathology favors vascular vulnerability and systemic metabolic dysregulation. Effective management requires more than simple monitoring of serum markers. This should target the molecular mechanisms that fuel cardiovascular and metabolic damage.

• Publication year

  2025

• Venue

  Maedica

• Publication date

  2025-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.26574/maedica.2025.20.3.591PMID 41403797PMCID PMC12631595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alteration in epigenetic profile in subclinical atherosclerosis and in high uric acid

  2025cited by this paper
• Hyperuricemia and its related diseases: mechanisms and advances in therapy

  2024cited by this paper
• Dyslipidemia and hyperuricemia: a cross-sectional study of residents in Wuhu, China

  2024cited by this paper
• Beyond the Scale: Investigating Adiponectin, ICAM-1, and VCAM-1 as Metabolic Markers in Obese Adolescents with Metabolic Syndrome

  2023cited by this paper
• Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies

  2023cited by this paper
• Hypertension and Dyslipidemia: the Two Partners in Endothelium-Related Crime

  2023cited by this paper
• The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications

  2023cited by this paper
• Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk

  2023cited by this paper
• Uric Acid and Oxidative Stress—Relationship with Cardiovascular, Metabolic, and Renal Impairment

  2022cited by this paper
• Naringenin Ameliorates Hyperuricemia by Regulating Renal Uric Acid Excretion via the PI3K/AKT Signaling Pathway and Renal Inflammation through the NF-κB Signaling Pathway.

  2022cited by this paper
• Hyperuricemia and Endothelial Function: Is It a Simple Association or Do Gender Differences Play a Role in This Binomial?

  2022cited by this paper
• Insulin Downregulates the Expression of ATP-binding Cassette Transporter A-I in Human Hepatoma Cell Line HepG2 in a FOXO1 and LXR Dependent Manner

  2022cited by this paper
• The Need for Individualized Risk Assessment in Cardiovascular Disease

  2022cited by this paper
• The Mechanism of the NLRP3 Inflammasome Activation and Pathogenic Implication in the Pathogenesis of Gout

  2022cited by this paper
• The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia

  2021cited by this paper
• Urate transport in health and disease.

  2021cited by this paper
• Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease

  2021cited by this paper
• Circulating microRNA alternations in primary hyperuricemia and gout

  2021cited by this paper
• Immunologic Aspects of Dyslipidemia: a Critical Regulator of Adaptive Immunity and Immune Disorders

  2021cited by this paper
• Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited.

  2020cited by this paper
• Genetic analysis of DNA methylation in dyslipidemia: a case-control study

  2020cited by this paper
• Lipoprotein Lipase and Its Regulators: An Unfolding Story.

  2020cited by this paper
• The Diabetes Mellitus–Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation

  2020cited by this paper
• Endothelial stiffening in dyslipidemia

  2019cited by this paper
• Hyperuricemia and Hypertension: Links and Risks

  2019cited by this paper
• Insulin promotes sodium transport but suppresses gluconeogenesis via distinct cellular pathways in human and rat renal proximal tubules.

  2019cited by this paper
• Insulin-induced de novo lipid synthesis occurs mainly via mTOR-dependent regulation of proteostasis of SREBP-1c

  2019cited by this paper
• ATP-binding cassette transporter A1 (ABCA1) expression in adipose tissue and its modulation with insulin resistance in obesity

  2019cited by this paper
• The PI3K/AKT pathway in obesity and type 2 diabetes

  2018cited by this paper
• Cell-specific histone modifications in atherosclerosis

  2018cited by this paper
• The role of oxidative stress and NADPH oxidase in the pathogenesis of atherosclerosis.

  2017cited by this paper
• Chronic Inflammatory Diseases and Endothelial Dysfunction.

  2016cited by this paper
• Insights into the Role and Interdependence of Oxidative Stress and Inflammation in Liver Diseases

  2016cited by this paper
• The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux.

  2016cited by this paper
• Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism.

  2016cited by this paper
• NLRP3 inflammasome: a novel link between lipoproteins and atherosclerosis

  2016cited by this paper
• Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis

  2016cited by this paper
• ABCG2: the molecular mechanisms of urate secretion and gout.

  2015cited by this paper
• The role of endothelial dysfunction driven by adipocitokines in the development and progression of microvascular complications in patients with type 1 and type 2 diabetes.

  2015cited by this paper
• Serum uric acid and the risk of cardiovascular and renal disease.

  2015cited by this paper
• Elevated Serum Uric Acid is Associated With Angiotensinogen in Obese Patients With Untreated Hypertension

  2014cited by this paper
• A novel JNK2/SREBP-1c pathway involved in insulin-induced fatty acid synthesis in human adipocytes

  2013cited by this paper
• MicroRNA associated with dyslipidemia and coronary disease in humans.

  2013cited by this paper
• The Vascular Endothelium and Human Diseases

  2013cited by this paper
• The genetics of hyperuricaemia and gout

  2012cited by this paper
• Allopurinol, quercetin and rutin ameliorate renal NLRP3 inflammasome activation and lipid accumulation in fructose-fed rats.

  2012cited by this paper
• Uric Acid Induces Hepatic Steatosis by Generation of Mitochondrial Oxidative Stress

  2012cited by this paper
• Uric Acid-Induced Endothelial Dysfunction Is Associated with Mitochondrial Alterations and Decreased Intracellular ATP Concentrations

  2012cited by this paper
• Adipokines in inflammation and metabolic disease

  2011cited by this paper
• Endothelial dysfunction: the first step toward coronary arteriosclerosis.

  2009cited by this paper
• Uric Acid: The Oxidant-Antioxidant Paradox

  2008cited by this paper
• Hyperuricemia induces endothelial dysfunction.

  2005cited by this paper
• Role of oxidative modifications in atherosclerosis.

  2004cited by this paper
• Impact of the renin-angiotensin system on lipid and carbohydrate metabolism

  2004cited by this paper
• Role of Endothelial Dysfunction in Atherosclerosis

  2004cited by this paper
• Endothelial Dysfunction: A Marker of Atherosclerotic Risk

  2003cited by this paper
• Inflammation and Atherosclerosis

  2002cited by this paper

• No citing papers are available for this paper.